AIRSUPRA (albuterol sulfate and budesonide) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. Approved for asthma. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AIRSUPRA is a metered-dose inhaler combining albuterol sulfate (short-acting bronchodilator) and budesonide (inhaled corticosteroid) for asthma treatment. It works through corticosteroid hormone receptor agonism to reduce airway inflammation and improve bronchial smooth muscle relaxation. The combination therapy addresses both acute symptom relief and chronic inflammation in a single device.
Peak-stage product with early claims volume suggests strong market adoption; commercial teams are likely focused on penetration and key account management expansion.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
GRANITE: Airsupra Effectiveness in the Real World
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Worked on AIRSUPRA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~5 years — strategic planning for patent cliff underway
AIRSUPRA career opportunities are concentrated in commercial sales and key account management, reflecting its peak-stage market position and competitive intensity. The 15 linked roles emphasize field-based selling, account penetration, and regional therapy expertise rather than clinical development or manufacturing roles.
15 open roles linked to this drug
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo